PRDM9 and lung carcinoma: Although these drugs currently show a partial advantage, in a study of the efficacy of histone methyltransferase G9a in lung cancer, Rowbotham found that G9a may increase the number of lung cancer stem cells and thus promote lung cancer progression (Rowbotham et al., 2018).